The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Elevation Oncology Inc (NASDAQ: ELEV) was $0.60 for the day, up 1.18% from the previous closing price of $0.59. In other words, the price has increased by $1.18 from its previous closing price. On the day, 0.68 million shares were traded. ELEV stock price reached its highest trading level at $0.6341 during the session, while it also had its lowest trading level at $0.5905.
Ratios:
Our analysis of ELEV’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 41.10 and its Current Ratio is at 41.10. In the meantime, Its Debt-to-Equity ratio is 0.38 whereas as Long-Term Debt/Eq ratio is at 0.38.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Piper Sandler on May 31, 2024, initiated with a Overweight rating and assigned the stock a target price of $10.
On May 14, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $8.
On March 01, 2024, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $7.JMP Securities initiated its Mkt Outperform rating on March 01, 2024, with a $7 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELEV now has a Market Capitalization of 35464080 and an Enterprise Value of -44468916.
Stock Price History:
Over the past 52 weeks, ELEV has reached a high of $5.83, while it has fallen to a 52-week low of $0.36. The 50-Day Moving Average of the stock is -2.71%, while the 200-Day Moving Average is calculated to be -77.18%.
Shares Statistics:
ELEV traded an average of 1.16M shares per day over the past three months and 832220 shares per day over the past ten days. A total of 59.11M shares are outstanding, with a floating share count of 49.99M. Insiders hold about 15.43% of the company’s shares, while institutions hold 84.40% stake in the company. Shares short for ELEV as of 1728950400 were 5948373 with a Short Ratio of 5.11, compared to 1726185600 on 6264972. Therefore, it implies a Short% of Shares Outstanding of 5948373 and a Short% of Float of 10.6300004.
Earnings Estimates
Elevation Oncology Inc (ELEV) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.19 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.77 and -$0.9 for the fiscal current year, implying an average EPS of -$0.82. EPS for the following year is -$0.88, with 7.0 analysts recommending between -$0.64 and -$1.07.
